Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients

References

• Halilova KI, Brown EE, Sarah L, et al. Markers of the treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol. 2012;2012:1–7. article ID 978396.
   Google Scholar
• Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013;124:16–25.
   Google Scholar
• van der Heijden JW, Dijkmans BAC, Scheper RJ, et al. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs—from bench to bedside. Nat Clin Prac Rheumatol. 2007;3(1):26–34.
   Google Scholar
• Weinblatt ME, Kaplan H, Germain FB, et al. Methotrexate in rheumatoid arthritis: a five-year prospective multicenter study. Arthritis Rheumatism. 1994;37(10):1492–1498.
   Google Scholar
• Kooloos MW, Huizinga TWJ, Guchelaar HJ, et al. Pharmacogenetics in treatment of rheumatoid arthritis. Curr Pharm Des. 2010;16(2):164–175.
   Google Scholar
• Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168–173.
   Google Scholar
• Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2008;47(3):249–255.
   Google Scholar
• Abali EE, Skacel EN, Celikkaya H, et al. Regulation of human dihydrofolatereductaseactivity and expression. Vitam Horm. 2008;79:268–287.
   Google Scholar
• Martianov I, Ramadass A, Serra Barros A, et al. Respression of the human dihydrofolatereductase gene by a non-coding interfering transcript. Nature. 2007;445(7128):666–670.
   Google Scholar
• Askari BS, Krajinović M. Dihydrofolatereductase gene variations in susceptibility to disease and treatment outcomes. Curr Genomics. 2010;11(8):578–583.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324.
   Google Scholar
• Jekić B, Luković L, Bunjevački V, et al. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur J Clin Pharmacol. 2013;69(3):377–383.
   Google Scholar
• Prevoo ML, van ‘T Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patents with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48.
   Google Scholar
• Milić V, Jekić B, Luković L, et al. Association of dihydrofolatereductase (DHFR)-317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. Clin Exp Rheuamtol. 2012;30(2):178–183.
   Google Scholar
• Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 1988;16(3):1215.
   Google Scholar
• Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet. 2006;7:781–791.
   Google Scholar
• Jorgensen AL, Williamson PR. Methodological quality of pharmacogenetic studies: issues in concern. Stat Med. 2008;27:6547–6569.
   Google Scholar
• Jekić B, Vejnović D, Milić V, et al. Association of 63/91 length polymorphism in the DHFR gene major promoter with toxicity of methotrexate in patients with rheumatoid arthritis. Pharmacogenetics. 2016;17(15):1687–1691. Epub 2016 Sep 16.
   Google Scholar
• Wessels JA, de Vries-Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with singe-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheumatol. 2006;54(4):1087–1095.
   Google Scholar
• Chandran V, Siannis F, Rahman P, et al. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. J Rheumatol. 2010;37(7):1508–1512.
   Google Scholar
• Liu L, Liu S, Wang C, et al. Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review. J Clin Rheumatol. 2018 Jul 2. (Epub ahead of print). DOI:10.1097/RHU0000000000000810
   Google Scholar
• Skacel N, Menon LG, Mishra PJ, et al. Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate treatment. J Biol Chem. 2005 Jun 17;280(24):22721–22731.
   Google Scholar
• Wolff JE, Jürgens H. Dexamethasone induced partial resistance to methotrexate in C6-glioma cells. Anticancer Res. 1994;14(4A):1585–1588.
   Google Scholar
• Fuksa L, Brcakova E, Kolouchova G, et al. Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats. Toxicology. 2010;267(1–3):165–171.
   Google Scholar
• Malysheva OA, Wahle M, Wagner U, et al. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. J Rheumatol. 2008;35(6):979–985.
   Google Scholar
• Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol. 1993;20(2):263–267.
   Google Scholar
• Wolff JE, Hauch H, Kühl J, et al. Dexamethasone increases hepatotoxicity of MTX in children with brain tumors. Anticancer Res. 1998;18(4B):2895–2899.
   Google Scholar